AbbVie Returns OSE-230 Development Rights After $48M Acquisition
AbbVie handed back preclinical and Phase I development of OSE-230 to OSE Therapeutics under a December 2025 amendment after acquiring global rights in February 2024 for $48 million. The move follows OSE’s pause of OSE-230 work to focus on late-stage candidates, cutting AbbVie’s R&D exposure to early-stage inflammation assets.
1. AbbVie’s $48M Acquisition of OSE-230
AbbVie acquired global rights to OSE-230 in February 2024 for $48 million, initially overseeing its preclinical and Phase I development in partnership with OSE Therapeutics.
2. Amendment Returns Development Rights
Under a December 2025 amendment, AbbVie relinquished preclinical and Phase I responsibilities for OSE-230 as OSE Therapeutics refocused its pipeline on later-stage assets, thereby reducing AbbVie’s exposure to early-stage inflammatory research.
Related News
JEPI
Active ETFs Shift Holdings Daily, Provide Downside Protection, Charge 0.4%-1% Fees
JEPI•
AAPL
Apple App Store Blocks 1 Billion Fake Accounts, Prevents $2.2B Fraud
AAPL•
LCLN
Lincoln International Debuts 12.6% Up, Valued at $2.3 Billion After $421M IPO
LCLN•
MA
Chargebacks911 Partners with acceptcards to Reduce Chargebacks as UK Card Use Tops £1 Trn
MA•
PRPO
Precipio Q1 Revenue Rises 30% to $6.71M; Adjusted EBITDA Falls to -$200K
PRPO•
Sources
SF